SOGROYA biosimilars — when can they launch?
SOGROYA (SOMAPACITAN-BECO) · BLA761156 · NOVO NORDISK INC
Where SOGROYA sits in the biosimilar timeline
BPCIA 12-year reference product exclusivity for SOGROYA extends to 2032 (6 years from today). Biosimilars cannot be approved by the FDA before this date. Biosimilar developers begin clinical comparability studies 4-6 years before the cliff.
Under the US Biologics Price Competition and Innovation Act (BPCIA), a reference biologic is protected from biosimilar competition for 12 years from FDA approval (with 4 years of data exclusivity preventing 351(k) submissions). Biosimilars enter via the abbreviated 351(k) pathway, which requires comparability — not exact identity — to the reference product.
Key dates for SOGROYA
| Event | Date | Status |
|---|---|---|
| FDA approval (BLA filed by NOVO NORDISK INC) | 2020-08-28 | Past |
| 4-year data exclusivity ends (first biosimilar 351(k) submission permitted) | 2024-08-28 | Past |
| 12-year reference product exclusivity ends (first biosimilar can be marketed) | 2032-08-28 | Future |
Note: composition-of-matter and method-of-use patent expiries (separate from BPCIA exclusivity) may set the actual launch window. See SOGROYA on Drug Landscape for the full patent picture.
Other NOVO NORDISK INC biologics
- NOVOLIN R — exclusivity to 2003-06-25
- NOVOLIN 70/30 — exclusivity to 2003-06-25
- NOVOLIN N — exclusivity to 2003-07-01
- NOVOLOG — exclusivity to 2012-06-07
- NORDITROPIN — exclusivity to 2012-06-20
- INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30 — exclusivity to 2013-11-01
- LEVEMIR — exclusivity to 2017-06-16
- ALHEMO — exclusivity to 2036-12-20
Sources
- FDA Purple Book — biologic license applications + BPCIA exclusivity
- SOGROYA drug profile — full patent estate, indications, clinical trials
- NOVO NORDISK INC patent portfolio
Not legal advice. BPCIA exclusivity may interact with composition-of-matter patents and patent term extensions — see the full drug profile for the consolidated picture.
Track SOGROYA biosimilar entry
Daily alerts when BPCIA exclusivity, ref-product patents, or biosimilar applications change. Free 3 watches, Pro 50.